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Computational Studies of Drug
Repurposing Targeting
P-Glycoprotein-Mediated
Multidrug-Resistance Phenotypes
in Agents of Neglected Tropical
Diseases
Nivedita Jaishankar, Sangeetha Muthamilselvan
and Ashok Palaniappan
Abstract
Mammalian ABCB1 P-glycoprotein is an ATP- dependent efflux pump with
broad substrate specificity associated with cellular drug resistance. Homologous to
this role in mammalian biology, the P-glycoprotein of agents of neglected tropical
diseases (NTDs) mediates the emergence of multidrug-resistance phenotypes. The
clinical and socioeconomic implications of NTDs are exacerbated by the lack of
research interest among Big Pharma for treating such conditions. This work aims to
characterise P-gp homologues in certain agents of key NTDs, namely (1) Protozoa:
Leishmania major,Trypanosoma cruzi; (2) Helminths: Onchocerca volvulus,
Schistosoma mansoni. Based on structural modelling of the organismal P-gp
homologues, potential antibiotics targeting these structures were identified based
on similarity and repurposing of existing drugs. Docking studies of the Pgp
receptor—antibiotic ligand complexes were carried out and the most tenable
target-ligand conformations assessed. The interacting residues were identified, and
binding pockets studied. The in silico studies yielded measurements of the relative
efficacy of the new drugs, which need experimental validation. Our studies could
lay the foundation for the development of effective synergistic or new therapies
against key neglected tropical diseases. The potential mechanisms of multidrug
resistance emergence in E. coli were examined.
Keywords: P-glycoprotein, neglected tropical diseases, multidrug resistance,
homology modeling, receptor-ligand docking, differential ligand affinity,
synergistic effects, leishmaniasis, trypanosomiasis, onchocerciasis, schistosomiasis
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1. Introduction
1.1 Multidrug resistance (MDR)
Bacterial evolution has been constrained to respond to the selection pressure of
antibiotics and combined with their reckless use and has led to the emergence of
varied defenses against antimicrobial agents. The main mechanisms whereby the
bacteria develop resistance to antimicrobial agents include enzymatic inactivation,
modification of the drug target(s), and reduction of intracellular drug concentration
by changes in membrane permeability or by the over expression of efflux pumps
[1]. Multidrug resistance efflux pumps are recognized as an important component
of resistance in both Gram-positive and Gram-negative bacteria [2]. Some bacterial
efflux pumps may be selective for one substrate or transport antibiotics of different
classes, conferring a multiple drug resistance (MDR) phenotype. With respect to
efflux pumps, they provide a self-defense mechanism whereby antibiotics are
extruded from the cell interior to the external environment. This results in sublethal
drug concentrations at the active site that in turn may predispose the organism to
the development of high-level target-based resistance [3]. Therefore, efflux pumps
are viable antibacterial targets, and identification and development of potent efflux
pump inhibitors is a promising and valid strategy potential therapeutic agents that
can rejuvenate the activity of antibiotics that are no longer effective against bacterial
pathogens. The world is searching for new tools to combat multidrug resistance.
1.2 P-glycoprotein
P-glycoprotein is a mammalianmultidrug-resistance protein belonging to the ATP-
binding cassette (ABC) superfamily [4]. It is an ATP-dependent efflux pump encoded
by theMDR1 gene and is primarily found in epithelial cells lining the colon, small
intestine, pancreatic ductules, bile ductules, kidney proximal tubes, the adrenal
gland, and the blood-testis and the blood-brain barrier [5]. This efflux activity of
P-glycoprotein, coupledwith its wide substrate specificity, is responsible for the reduc-
tion in bioavailability of drugs as it extrudes all foreign substances such as drugs and
xenobiotics out of the cells. ATPhydrolysis provides energy for the efflux of drugs from
the inner leaflet of the cellmembrane [6, 7]. This protein is believed to have evolved as a
defensemechanism against toxic compounds and prevent their entry into the cytosol [8].
P-glycoprotein confers resistance to a wide range of structurally and
functionally diverse compounds, which has resulted in the emergence of multidrug
resistance in medically relevant microorganisms. The pharmacodynamic role of
P-glycoprotein in parasitic helminths has widespread clinical and socioeconomic
implications, exacerbating the problem of neglected tropical diseases (NTDs)
whose causative agents are helminths and protozoa.
Sheps et al. [9] reported that 15 P-glycoproteins are present in Caenorhabditis
elegans, and Laing et al. [10] reported that 10 homologous P-glycoproteins were
present in Haemonchus contortus. A bioinformatic and phylogenetic study conducted
by Bourguinat et al. [11] on the Dirofilaria immitis genome identified three
orthologous ABC-B transporter genes. These genes are suspected to be responsible
for the P-glycoprotein-mediated drug extrusion of melarsomine in D. immitus and
other parasites.
1.3 Neglected tropical diseases
Neglected tropical diseases (NTDs) encompass 17 bacterial, parasitic, and viral
diseases that prevail in tropical and subtropical conditions in 149 countries and
affect more than 1 billion people worldwide, according to WHO.
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1.3.1 Leishmaniasis
Leishmaniasis is a disease caused by parasites of the Leishmania type. It is spread
by the bite of certain types of sandflies [12]. The disease can present in three main
ways: cutaneous, mucocutaneous, or visceral leishmaniasis [13]. The cutaneous
form presents with skin ulcers, whereas the mucocutaneous form presents with
ulcers of the skin, mouth, and nose [12]. Leishmaniasis is transmitted by the bite of
infected female phlebotomine sand flies [14] which can transmit the protozoa
Leishmania.
Gammaro et al. [12] first reported that the overexpression of P-glycoprotein in
Leishmania species was responsible for the drug resistance of the organisms against
drugs such as methotrexate. The multidrug resistance has been associated with
several ATP-binding cassette transporters including MRP1 (ABCC1) and P-
glycoprotein (ABCB1). Wyllie et al. [15] demonstrated the presence of metal efflux
pumps in the cell membrane of all Leishmania species. Soares et al. [16] reported
that natural or synthetic modulators of human P-glycoprotein such as flavonoids
restore sensitivity to pentamidine, sodium stibogluconate, and miltefosine by mod-
ulating intracellular drug concentrations.
1.3.2 Onchocerciasis
Onchocerciasis, also known as river blindness, is a disease caused by infection
with the parasitic worm Onchocerca volvulus and is transmitted by the bite of an
infected black fly of the Simulium type. Symptoms include severe itching, bumps
under the skin, and blindness. It is the second most common cause of blindness due
to infection, after trachoma, according to WHO. Usually, many bites are required
before infection occurs. A vaccine against the disease does not exist. Prevention is
by avoiding being bitten by flies.
Ivermectin (IVM) is a semisynthesized macrocyclic lactone that belongs to the
avermectin class of compounds. It is administered en masse and but is effective only
against microfilariae [17]. Bourguinat et al. [11] have found evidence of IVM resis-
tance in Onchocerca volvulus. The clinical trial sampled patients before and after
IVM treatment over a period of 3 years. The nodules collected from the patients
contained IVM-resistant O. volvulus worms.
1.3.3 Schistosomiasis
Schistosomiasis is a disease caused by infection with one of the species of
Schistosoma helminthic flatworms known as flukes belonging to the class Trematoda
of the phylum Platyhelminthes. There are three main species of Schistosoma associ-
ated with human disease: Schistosoma mansoni and Schistosoma japonicum cause
intestinal schistosomiasis, and Schistosoma haematobium causes genitourinary schis-
tosomiasis. Other Schistosoma species have been recognized less commonly as agents
of intestinal schistosomiasis in humans [18]. Pinto-Almeida et al. [19] demonstrated
that drug resistance by Schistosoma mansoni to praziquantel (commonly employed
drug) is mediated by efflux pump proteins, including P-glycoprotein and multidrug
resistance-associated proteins.
1.3.4 Trypanosomiasis
The trypanosomiasis consists of a group of diseases caused by parasitic protozoa
of the genus Trypanosoma. There are two main parasites such as Trypanosoma
brucei, which causes the sleeping sickness or human African trypanosomiasis and
Trypanosoma cruzi, which causes the Chagas’ disease or American trypanosomiasis
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[20]. These diseases are transmitted by several arthropod vectors such as Glossina
and Triatominae. Chaga’s disease causes 21,000 deaths per year mainly in Latin
America [21]. Benznidazole and Nifurtimox, only available drugs, however, have
limited efficacy in the advanced stages of the disease [22]. Liu et al. [23] and Rappa
et al. [24] concluded that Trypanosoma cruzi develops resistance to the drugs after
prolonged treatment. It was shown that this happens due to the overexpression of
the MDR1 gene, at high levels of the drug, which accumulates in the cells over time.
Campos et al. [25] demonstrated that the drug resistance is continued throughout
the life cycle of the worm.
2. Methods
The methodology is essentially similar to that in our earlier study on P-
glycoproteins in priority infectious agents [26].
2.1 Determining the full helminthic complement of efflux pump proteins
homologous to mammalian P-glycoprotein
The protein sequence of the human P-glycoprotein (P08183) was obtained from
the SWISS-PROT database. The position-specific iterated BLAST (PSI-BLAST) was
performed against a search set of nonredundant protein sequences in the organism
of interest, using hPGP as the query. Through a PSI-BLAST search, a large set of
related proteins are compiled. It is used to identify distant evolutionary relation-
ships between protein sequences [27]. In the algorithm, parameters were set with an
E-value of 0.001, and the scoring matrix BLOSUM62 was used. This step was
performed on all four organisms of interest (Leishmania major, Onchocerca volvulus,
Schistosoma mansoni, and Trypanosoma cruzi). Hundreds of hits were obtained for P-
glycoprotein, and these results were prioritized according to predetermined param-
eters such as medical relevance, annotation status, and the presence of conserved
regions. Sequences having a high percentage of sequence identity and query cover-
age were prioritized. Specific UniProt searches of these protein sequences were
performed using the accession number. The results were analyzed, and the P-
glycoprotein sequence of each organism was finalized.
2.2 Multiple sequence alignment
The templates chosen for multiple sequence alignment (MSA) were 4M1M (Mus
musculus), 4F4C (Caenorhabditis elegans), 3WME (Cyanidioschyzon merolae), 2HYD
(Staphylococcus aureus), 3B5Z (Salmonella enterica). These five metazoan, algal, and
bacterial templates were used due to their high sequence identity with the hPGP
sequence. The target sequences and the five templates were aligned using ClustalX
2.1 [28]. MSA was performed in order to infer the homology and evolutionary
relationship between the sequences of the biological data set. The clustering algo-
rithm used was Neighbor Joining (NJ). The phylogenetic distance between the
target sequence and the templates was calculated.
2.3 Homology modeling
The chosen P-glycoprotein sequences were used as target sequences for model-
ing using software such as SWISS-MODEL. SWISS-MODEL is an open-source,
structural bioinformatics tool used for the automated comparative modeling of
three-dimensional protein structures [29, 30]. Several P-glycoprotein structures
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were modeled for each organism, using multiple templates. The templates having
high sequence similarity with the target sequences were given preference. The
models were built, and the PDB files of the structures were obtained.
2.4 Structure validation
The validity of the structures was checked using Procheck, an open source tool
used to assess the reliability of the protein structure. It is a part of the SWISS-
MODEL server. The structures were refined using energy-minimization protocols,
and the least energetic structure corresponding to each protein was chosen for
docking studies. The criteria used to assess the quality of the structure include
model geometry and the Ramachandran plot. The Ramachandran plot describes the
rotation of the polypeptide backbone around the N-Cα (ϕ) and C-Cα (ψ) bonds. It
provides an overview of the distribution of the torsion angles over the core,
allowed, generous, and disallowed regions. The three main parameters used to
select the structures were:
1.Overall Ramachandran value
2.Phylogenetic tree distance
3.Taxonomy
2.5 Creation of the ligand dataset
The ligand data set was created by surveying the literature to determine the
drugs which the pathogenic helminths are both sensitive and resistant to. Drug
resistance which was conferred via efflux pump activity was given importance. This
set of ligands was created for each efflux pump, comprising known and potential
antibiotics. The canonical simplified molecular-input line-entry system (SMILES) of
each drug was retrieved from the PubChem database. The PDB model of each
antibiotic was then generated using MarvinView by converting the canonical
SMILES [31].
2.6 Protein and ligand preparation
The efflux pump proteins and ligands were individually docked using the
AutoDock Version 4.2.6 suite of programs [32]. The software consists of two main
programs: AutoGrid, which precalculates a set of grid points on the receptor, and
AutoDock, which docks the ligand to the receptor through the grids. The PDB files
of the P-glycoprotein structures and the ligands were modified through the addition
of Gasteiger charges, followed by the addition and merging of hydrogen atoms to
each structure. These modified structures were then saved as PDBQT files using the
AutoDock tools. A uniform grid box was then defined and centered in the internal
binding cavity of each P-glycoprotein structure, and the affinity maps were gener-
ated using AutoGrid. This procedure was repeated for each protein-drug complex.
2.7 Molecular docking of the helminthic efflux pumps with known and
potential antibiotics
Each drug was individually docked with each target protein using AutoDock
4.2.6. The local search algorithm used was the Lamarckian genetic algorithm, set to
its default parameters. The docking parameters were set to 250,000 cycles per run
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and 10 runs per protein-drug complex, to obtain the 10 best poses for each complex.
The best pose was defined as the conformation having the least binding energy. The
10 poses obtained for each receptor-ligand pair were clustered at 2.0 Å r.m.s. to
validate the convergence to the best pose. The AutoDock was run, and the PDBQT
file of the best pose of each docked complex was generated.
The results were analyzed to verify whether the pathogenic strain could develop
resistance to known antibiotics using efflux pump activity and if the novel antibi-
otics could be effective against the development of such resistance.
2.8 Calculation of differential ligand binding affinity
The differential binding affinities of the repurposed ligands were determined
using the conventionally used drugs as a baseline. A lower value is indicative of a
more stable complex. The differential affinity of the potential drug for a given
efflux pump protein relative to the known drug is estimated as the difference in the
binding energies of the known and potential drugs, as given by Eq. (1):
∆∆Ginvest:known ¼ ∆Gbind,potential  ∆Gbind,known (1)
where ∆∆Ginvest.known = differential ligand affinity, kcal/mol; ∆Gbind = free
energy of binding, kcal/mol.
2.9 Identification of interacting residues in each docked complex
The best pose of each docked complex was viewed using RasMol [33], and all
interacting residues within a radius of 4.5 Å of the ligand were selected. The PDBQT
file of each restricted complex was saved as a PDB file. The interacting residues of
each docked complex were then analyzed.
3. Results and discussion
Extensive literature searches on Neglected Tropical Diseases (NTDs) showed
that leishmaniasis, onchocerciasis, schistosomiasis, and trypanosomiasis have
started exhibiting multidrug resistance, mediated by P-glycoprotein efflux pumps
[11, 12, 25, 34]. New drugs targeting NTD’s are undergoing clinical trials [35–37],
and efforts are being taken to uncover the mechanisms of drug resistance employed
by the causative helminths.
The sequence identity of each helminthic P-glycoprotein with the human P-
glycoprotein (hPGP) which was retrieved from the UniProt database (UniProt ID:
P08183) was determined by running a PSI-BLAST.
3.1 Psi-blast analysis
The PSI-BLAST was performed on each target organism using hPGP as the
query. The results were refined according to predetermined parameters such as
medical relevance, annotation status, and the presence of conserved regions. The
chosen efflux pump protein sequences were shown in Table 1.
The top hits of each PSI-BLAST were analyzed, and the hit having the highest
Max Score was chosen only in the case of Leishmania major and Onchocerca volvulus.
These protein sequences were fully annotated and had high sequence identities over
a large portion of the protein sequence. The top hits of the PSI-BLAST of
Schistosoma mansoni and Trypanosoma cruzi with hPGP yielded results having high
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Max Scores, but low query coverage. These protein sequences were also found to be
unannotated. For these reasons, the proteins which had a lower Max Score in
comparison to other results, but satisfied other parameters, were chosen.
3.2 Template selection and multiple sequence alignment
Certain metazoan, algal and bacterial crystal structures shown in Table 2 were
selected as potential templates for homology modeling [38].
Each target protein sequence was aligned with the set of chosen templates using
ClustalX 2.1. The MSA between Leishmania major and the 4M1M and 4F4C tem-
plates showed the highest sequence identity, as shown in Figure 1. Additionally, the
phylogenetic distances between the sequences were calculated using the NJ
algorithm (Table 3).
3.3 Homology modeling
The chosen P-glycoprotein sequences of the organisms were used as target
sequences for homology modeling using the SWISS-MODELER. Each protein was
modeled using several templates, and the predetermined templates were used if
they were found to have a fairly high GMQE score. Each modeled structure was
saved as a PDB file. The results are summarized in Table 4.
Global Model Quality Estimation (GMQE) is a score that provides an estimation
of the quality of the alignment. It is expressed as a value between 0 and 1, where the
reliability of the model is directly proportional to the score. The GMQE of the
homology models are found to be (mostly) between 0.60 and 0.70 for all organisms,
with the exception of Trypanosoma cruzi, which gave scores in the range 0.29–0.52.
The templates 4M1M, 4F4C, and 3WME were found to be comparatively more
reliable. Hence, only the protein structures modeled using these templates were
used for further validation studies.
Organism Name of
protein
Sequence
length
% of
identity
Query
coverage
Max
score
Leishmania major P-glycoprotein 1341 36% 98% 767
Onchocerca volvulus P-glycoprotein 1278 37% 97% 776
Schistosoma
mansoni
SMDR2 1254 40% 98% 889
Trypanosoma cruzi P-glycoprotein 1034 29% 30% 79.7
Table 1.
PSI-BLAST results of the target organisms using hPGP as the query.
Template Organism
4M1M Mus musculus
4F4C Canorhabditis elegans
3WME Cyanidioschyzon merolae
2HYD Staphylococcus aureus
3B5Z Salmonella enteric
Table 2.
Templates chosen for multiple sequence alignment.
7
Computational Studies of Drug Repurposing Targeting P-Glycoprotein-Mediated…
DOI: http://dx.doi.org/10.5772/intechopen.93175
Please use Adobe Acrobat Reade  to read this book chapter for free.
Just open this sam  document with Adobe Reader.
If you do not have it, you can download it here.
You can freely access the chapter at the Web Viewer here.
Secur g Con ection...Acrobat is locking documen l ading.com
r
File cannot be found.
3.4 Structure validation
The quality of each structure was assessed using Procheck. Criteria such as
model geometry and the Ramachandran plot were used to validate the structures.
The PDB file of each structure was used to run the Procheck, and the
Ramachandran plot values were obtained. The Ramachandran values are summa-
rized in Table 5.
Figure 1.
Multiple sequence alignment of the target sequence P-glycoprotein of Leishmania major (tr_Q4Q3A6) with the
templates of interest.
8
E. Coli Infections - Importance of Early Diagnosis and Efficient TreatmentPlease use Adobe Acrobat Reader to read this book chapter for free.
Just open this same document with Adobe Reader.
If you do not have it, you can download it here.
You can freely access the chapter at the Web Viewer here.
Securin  Connect on...Acrobat is locking documen loading.com
r
File cannot be found.
Template Phylogenetic distance
Leishmania major Onchocerca volvulus Schistosoma mansoni Trypanosoma cruzi
4M1M 0.685 0.648 0.646 0.847*
4F4C 0.642 0.638 0.605 0.861
3WME 0.653 0.679 0.649 0.867
2HYD 0.72 0.709 0.694 0.826
3B5Z 0.731 0.707 0.698 0.841
*The distance between T. cruzi and 4M1M is prioritized as the 4M1M and 4F4C templates were found to have higher sequence
identity with the helminthic P-glycoproteins.
Bold values signify the final template in the case of each agent.
Table 3.
Phylogenetic distance matrix between the target sequence of each organism and the templates.
Organism Template Sequence identity Query coverage GMQE
Leishmania major 4F4C 34.43 0.91 0.64
4M1M 36.09 0.90 0.65
3WME 37.30 0.43 0.29
4Q9I 36.20 0.90 0.65
4KSC 38.25 0.90 0.64
4KSB 38.25 0.90 0.64
5KPJ 38.25 0.90 0.66
Onchocerca volvulus 4F4C 38.83 0.97 0.69
4M1M 37.10 0.96 0.69
3WME 31.75 0.44 0.33
3G5U 38.77 0.95 0.66
4KSB 38.77 0.95 0.67
4Q9I 36.97 0.95 0.69
4LSG 38.77 0.95 0.67
Schistosoma mansoni 4F4C 38.60 0.97 0.69
4M1M 36.09 0.90 0.65
3G5U 39.41 0.97 0.68
3G60 42.11 0.95 0.68
5KPJ 39.52 0.97 0.70
4KSC 42.11 0.95 0.69
4KSB 42.11 0.95 0.69
4LSG 39.41 0.97 0.69
Trypanosoma cruzi 4F4C 15.11 0.81 0.45
4M1M 14.36 0.78 0.29
3WME 18.37 0.51 0.33
4KSC 14.23 0.79 0.44
3G5U 14.46 0.78 0.43
5TSI 23.43 0.90 0.52
4LSG 14.46 0.78 0.43
Table 4.
Homology modeling results.
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The structures were finalized by analyzing overall Ramachandran value, Phylo-
genetic tree distance, and taxonomy parameters. The 4F4C template was found to
suitable for all the organisms excluding Leishmania major, for which the 4M1M
template was selected (Table 5).
3.4.1 Validation of the P-glycoprotein structure modeled using the 4M1M template for
Leishmania major
The Ramachandran plots having a core region of at least 90% are prioritized for
further studies. The core, allowed, generous and disallowed regions are colored and
distinguished (Figure 2). The red, brown, and yellow regions represent the favored,
allowed, and generously allowed regions.
A more comprehensive analysis of the structure is provided by other programs
that generate other data such as Phi-Psi graphs and Chi1-Chi2 plots for each residue
type. Each Phi-Psi plot provides an analysis of the torsion angle of each residue type.
The red, brown, and yellow regions represent the favored, allowed, and generously
allowed regions (shown in Figure 3).
The Chi1-Chi2 plot describes the side-chain torsion angles combinations for each
amino acid [28]. The darker regions indicate a more favorable angle combination
(shown Figure 4).
3.4.2 Validation of the P-glycoprotein structure modeled using the 4F4C template for
Onchocerca volvulus, Schistosoma mansoni and Trypansoma cruzi
For all the three P-glycoproteins, the structures were modeled using the 4F4C
template and as such and showed remarkable structural similarity with respect to
the Ramachandran plot (90.8% in the core region), and residue torsion angles.
Figures 5–7 summarize this exercise.
3.5 Creation of the ligand dataset
Upon extensive survey of the literature, a comprehensive data set of the known
and potential drugs was compiled (Table 6). The list of potential drugs comprises
of both unapproved, investigational drugs that are undergoing phase trials, and
FDA approved antibiotics. In this study, these known drugs have been repurposed
for other helminthic diseases.
3.6 Molecular docking of the helminthic efflux pumps with known and
potential antibiotics
The molecular docking was carried out using the AutoDock suite of tools. The
search algorithm used was the Lamarckian Genetic Algorithm, and the docking
parameters were set to 10 runs per protein-drug complex. Each docked complex
yielded 10 poses, and the best pose was defined as the conformation possessing the
least free binding energy.
3.6.1 Molecular docking results of benznidazole with P-glycoprotein (Leishmania major)
The drug benznidazole is docked with P-glycoprotein (Leishmania major), and
their interaction is studied (Table 7). The best pose has a free binding energy of
5.00 kcal/mol. The clustering was performed at 2.0 Å r.m.s. to validate the con-
vergence to the best pose. The clustering figure (Figure 8) shows closer peaks near
2.5 kcal/mol, whereas the least binding energy of the complex, that is, most
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Leishmania major
Template Core region Additionally allowed region Generously allowed region Disallowed region No. of residues Query coverage Sequence identity Phylogenetic distance
4F4C 90.8 8.1 1.2 0 1250 0.43 34.43 0.685
4M1M 92 6.4 1.4 0.2 1188 0.9 36.09 0.642
3WME 94.6 4.6 0.4 0.4 573 0.43 36.46 0.653
Onchocerca volvulus
Template Core region Additionally allowed region Generously allowed region Disallowed region No. of residues Query coverage Sequence identity Phylogenetic distance
4F4C 90.8 8.1 1.2 0 1250 0.97 38.83 0.648
4M1M 91.1 7.6 1.2 0.1 571 0.95 37.1 0.638
3WME 93.1 5.8 0.6 0.6 1180 0.45 33.51 0.679
Schistosoma mansoni
Template Core region Additionally allowed region Generously allowed region Disallowed region No. of residues Query coverage Sequence identity Phylogenetic distance
4F4C 90.8 8.1 1.2 0 1250 0.97 38.6 0.646
4M1M 91.1 6.9 1.8 0.2 572 0.46 36.6 0.605
3WME 93.7 5.8 0.2 0.4 567 0.45 38.31 0.649
Trypanosoma cruzi
Template Core region Additionally allowed region Generously allowed region Disallowed region No. of residues Query coverage Sequence identity Phylogenetic distance
4F4C 90.8 8.1 1.2 0 1250 0.81 15.11 0.847
4M1M 86.0 11.9 1.8 0.2 1034 0.51 17.80 0.867
3WME 89.8 8 1.6 0.6 573 0.51 18.37 0.861
Table 5.
Justification of the template chosen for each organism using the Ramachandran plot values and the phylogenetic distance between the target protein and the template.
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Figure 2.
(a) The Ramachandran plot generated for P-glycoprotein (Leishmania major), modeled using the 4M1M
template and (b) plot statistics of the P-glycoprotein (Leishmania major), modeled using the 4M1M template.
Figure 3.
Phi-psi plot of residues of the P-glycoprotein structure of Leishmania major, modeled using the 4M1M template
(a) Ala, (b) Arg, and (c) Asn.
Figure 4.
Chi1-Chi2 plot of residues of the P-glycoprotein structure of Leishmania major, modeled using the 4M1M
template (a) Arg, (b) Asn and (c) Asp.
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Figure 5.
(a) The Ramachandran plot generated for P-glycoprotein (Onchocerca volvulus), modeled using the 4F4C
template and (b) plot statistics of the P-glycoprotein (Onchocerca volvulus), modeled using the 4F4C
template.
S. no. Drug PubChem CID 3-D Structure
1. Albendazole 2082
2. Amphotericin B 5280965
3. Artesunate 65664
4. Benznidazole 5798
5. Cladosporin 13990016
6. Dapsone 2955
7. Diethylcarbamazine 15432
8. Emodepside 6918632
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S. no. Drug PubChem CID 3-D Structure
9. Fexinidazole 68792
10. Flubendazole 35802
11. Fluconazole 3365
12. Furozan 67517
13. Imatinib 5291
14. Ivermectin 6321424
15. Jaspamide 9831636
16. Mebendazole 4030
17. Metrifonate 5853
18. Miltefosine 3599
19. Moxidectin 9832912
20. Niclosamide 4477
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S. no. Drug PubChem CID 3-D Structure
21. Nifurtimox 6842999
22. Oxamniquine 4612
23. Paromomycin 165580
24. Pentamidine 4735
25. Posaconazole 468595
26. Praziquantel 4891
27. Ravuconazole 467825
28. Sodium stibogluconate 76968133
29. Suramin 5361
30. Terbinafine 1549008
31. Thiabendazole 5430
32. Tipifarnib 159324
3D structures of the drugs are visualized using python molecular viewer (PMV-1.5.6).
Table 6.
PubChem compound ID and 3D structure of the ligands used for docking studies.
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clustering is at 5.66 kcal/mol. This shows that convergence to the best pose can be
achieved through consecutive dockings with more iterations. Figure 8(b) depicts
the binding site on the receptor, and Figure 8(c) shows the interacting residues in
the benznidazole-P-glycoprotein (Leishmania major) docked complex viewed
through RasMol 2.1.
Figure 6.
Phi-psi plot of residues of the P-glycoprotein structure of Onchocerca volvulus, modeled using the 4F4C
template (a) Ala, (b) Arg, and (c) Asn.
Rank of complex Free binding energy (kcal/mol)
1 5.00
2 4.84
3 4.2
4 4.41
5 3.77
6 3.48
7 2.96
8 2.64
9 2.54
10 2.48
Table 7.
Interaction of the drug benznidazole with P-glycoprotein (Leishmania major).
Figure 7.
Chi1-Chi2 plot of residues of the P-glycoprotein structure of Onchocerca volvulus, modeled using the 4F4C
template. (a) Arg, (b) Asn, and (c) Asp.
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Figure 8.
(a) Clustering analysis of the benznidazole- P-glycoprotein docked complex. (b) Location of the binding site on
the receptor (P-glycoprotein [Leishmania major]). (c) The interacting residues in the benznidazole-
P-glycoprotein (Leishmania major) docked complex is viewed using RasMol 2.1.
Rank of complex Free binding energy (kcal/mol)
1 5.29
2 5.01
3 4.78
4 5.14
5 5.08
6 5.02
7 4.59
8 4.53
9 4.42
10 34.78
Table 8.
Interaction of the drug niclosamide with P-glycoprotein (Onchocerca volvulus).
Figure 9.
(a) Clustering analysis of the niclosamide- P-glycoprotein docked complex. (b) Location of the binding site on
the receptor (P-glycoprotein [Onchocerca volvulus]). (c) The interacting residues in the niclosamide- P-
glycoprotein (Onchocerca volvulus) docked complex is viewed using RasMol 2.1.
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Rank of complex Free binding energy (kcal/mol)
1 5.83
2 5.51
3 5.21
4 4.71
5 4.47
6 4.15
7 3.57
8 9.34
9 29.83
10 36.47
Table 9.
Interaction of the drug Praziquantel with P-glycoprotein (Schistosoma mansoni).
Figure 10.
(a) Clustering analysis of the Praziquantel-P-glycoprotein docked complex. (b) Location of the binding site on
the receptor (P-glycoprotein [Schistosoma mansoni]). (c) The interacting residues in the Praziquantel-
P-glycoprotein [Schistosoma mansoni] docked complex are viewed using RasMol 2.1.
Rank of complex Free binding energy (kcal/mol)
1 6.23
2 6.04
3 5.67
4 4.81
5 5.92
6 5.25
7 4.89
8 4.83
9 4.15
10 3.34
Table 10.
Interaction of the drug cladosporin with P-glycoprotein (Trypanosoma cruzi).
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3.6.2 Molecular docking results of niclosamide with P-glycoprotein
(Onchocerca volvulus)
The best pose has a free binding energy of 5.29 kcal/mol (Table 8). The
clustering figure shows the most number of conformations at 1.30 kcal/mol
(Figure 9). Figure 9(b) depicts the binding site on the receptor, and Figure 9(c)
shows the interacting residues in the niclosamide-P-glycoprotein (Onchocerca vol-
vulus) docked complex viewed through RasMol 2.1.
3.6.3 Molecular docking results of praziquantel with P-glycoprotein
(Schistosoma mansoni)
The best pose has a free binding energy of 5.83 kcal/mol (Table 9). The
clustering figure (Figure 10) shows the most number of conformations at
5.0 kcal/mol. Figure 10(b) depicts the binding site on the receptor, and
Figure 10(c) shows the interacting residues in the Praziquantel-P-glycoprotein
(Schistosoma mansoni) docked complex viewed through RasMol 2.1.
3.6.4 Molecular docking results of cladosporin with P-glycoprotein
(Trypanosoma cruzi)
The best pose has a free binding energy of 6.23 kcal/mol (Table 10). The
clustering figure (Figure 11) shows the most number of conformations at5.0 kcal/
mol. Figure 11(b) depicts the binding site on the receptor, and Figure 11(c) shows
the interacting residues in the the cladosporin-P-glycoprotein (Trypanosoma cruzi)
docked complex viewed through RasMol 2.1.
These steps were carried out for each receptor-ligand complex, and the least free
binding energy of each docked complex was determined. These results are summa-
rized in Table 11.
3.7 Calculation of differential ligand binding affinity
The differential affinity of the potential drug for a given efflux pump protein
relative to the known drug is estimated as the difference between the binding
energies of the known and potential drugs.
Figure 11.
(a) Clustering analysis of the cladosporin-P-glycoprotein docked complex. (b) Location of the binding site on
the receptor (P-glycoprotein [Trypanosoma cruzi]). (c) The interacting residues in the cladosporin-
P-glycoprotein [Trypanosoma cruzi] docked complex are viewed using RasMol 2.1.
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Known drugs Free binding energy Investigational drugs Free binding energy
L. major Amphotericin B 6.44 Cladosporin 6.42
Fluconazole 3.12 Jaspamide 5.98
Pentamidine 2.67 Nifurtimox 5.66
Miltefosine 1.21 Praziquantel 5.59
Dapsone 5.48
Benznidazole 5
Tipifarnib 4.54
Flubendazole 4.36
Terbinafine 4.25
Sodium stibogluconate 3.7
Paromomycin 3.07
Meglumine antimoniate
T. cruzi Nifurtimox 5.22 Cladosporin 6.23
Benznidazole 5.02 Tipifarnib 5.87
Jaspamide 5.82
Fexinidazole 4.62
Suramin 4.25
Ravuconazole 3.69
Posaconazole 2.52
AN2690
O. volvulus Mebendazole 5.36 Praziquantel 6.16
Albendazole 5.22 Moxidectin 5.53
Suramin 4.79 Niclosamide 5.29
Diethylcarbamazine 3.76 Flubendazole 4.58
Ivermectin 1.35 Thiabendazole 4.35
Metrifonate 2.09
Emodepside 1.92
S. mansoni Praziquantel 5.83 Cladosporin 6.07
Mebendazole 5.1 Jaspamide 6.06
Oxamniquine 4.4 Niclosamide 5.72
Albendazole 3.83 Nifurtimox 5.62
Artesunate 5.12
Benznidazole 4.41
Tipifarnib 4.38
Imatinib 4.29
Furozan 4.27
Suramin 3.85
Metrifonate 3.54
Table 11.
Free binding energy of all known and investigational drugs, including repurposed antibiotics.
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Leishmaniasis ∆G
unknown
∆∆G
amphotericin B
∆∆G
fluconazole
∆∆G
pentamidine
∆∆G
miltefosine
Cladosporin 6.42 0.02 3.3 3.75 7.63
Jaspamide 5.98 0.46 2.86 3.31 7.19
Nifurtimox 5.66 0.78 2.54 2.99 6.87
Praziquantel 5.59 0.85 2.47 2.92 6.8
Dapsone 5.48 0.96 2.36 2.81 6.69
Benznidazole 5 1.44 1.88 2.33 6.21
Tipifarnib 4.54 1.9 1.42 1.87 5.75
Flubendazole 4.36 2.08 1.24 1.69 5.57
Terbinafine 4.25 2.19 1.13 1.58 5.46
Sodium
stibogluconate
3.7 2.74 0.58 1.03 4.91
Paromomycin 3.07 3.37 0.05 0.4 4.28
Trypanosomiasis ∆G unknown ∆∆G Benznidazole ∆∆G Nifurtimox
Cladosporin 6.23 1.21 1.01
Tipifarnib 5.87 0.85 0.65
Jaspamide 5.82 0.8 0.6
Fexinidazole 4.62 0.4 0.6
Suramin 4.25 0.77 0.97
Ravuconazole 3.69 1.33 1.53
Posaconazole 2.52 2.5 2.7
Onchocerciasis ∆G
unknown
∆∆G
Mebendazole
∆∆G
Albendazole
∆∆G
Suramin
∆∆G
Diethylcarbamazine
∆∆G
Ivermectin
Praziquantel 6.16 0.8 0.94 1.37 2.4 4.81
Moxidectin 5.53 0.17 0.31 0.74 1.77 4.18
Niclosamide 5.29 0.07 0.07 0.5 1.53 3.94
Flubendazole 4.58 0.78 0.64 0.21 0.82 3.23
Thiabendazole 4.35 1.01 0.87 0.44 0.59 3
Metrifonate 2.09 3.27 3.13 2.7 1.67 0.74
Emodepside 1.92 3.44 3.3 2.87 1.84 0.57
Schistosomiasis ∆G
unknown
∆∆G
Praziquantel
∆∆G
Mebendazole
∆∆G
Oxamniquine
∆∆G
Albendazole
Cladosporin 6.07 0.24 0.97 1.67 2.24
Jaspamide 6.06 0.23 0.96 1.66 2.23
Niclosamide 5.72 0.11 0.62 1.32 1.89
Nifurtimox 5.62 0.21 0.52 1.22 1.79
Artesunate 5.12 0.71 0.02 0.72 1.29
Benznidazole 4.41 1.42 0.69 0.01 0.58
Tipifarnib 4.38 1.45 0.72 0.02 0.55
Imatinib 4.29 1.54 0.81 0.11 0.46
Furozan 4.27 1.56 0.83 0.13 0.44
Suramin 3.85 1.98 1.25 0.55 0.02
Metrifonate 3.54 2.29 1.56 0.86 0.29
Table 12.
Differential ligand binding affinity for each known-potential drug pair.
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∆∆Ginvest: ¼ ∆Gbind,potential  ∆Gbind,known
where ∆∆Ginvest. = differential ligand affinity, kcal/mol;∆Gbind = free energy of
binding, kcal/mol.
For each disease, the differential ligand binding affinity is calculated for every
known-potential drug pair. The ∆∆Ginvestiational values are given in Table 12. All
values are expressed in kcal/mol. The drugs having ∆∆Ginvest values greater than the
∆Ginvest. values may have better antihelminthic activity.
All values are expressed in kcal/mol. It can be inferred from these results that
many of the repurposed antiparasitic drugs show promise for treatment against
other helminths. The results shown in Table 12 serve as an indicator of which drugs
may be promising antihelminthics:
1.Leishmaniasis: Cladosporin (7.63 kcal/mol), Jaspamide (7.19 kcal/mol),
and Nifurtimox (6.87 kcal/mol).
2.Trypanosomiasis: Cladosporin (1.21 kcal/mol) and Tipifarnib (0.85 kcal/
mol)
Receptor Drug Interacting residues
4M1M Amphotericin B Thr172, Asp173, Ser176, Ala683, Asp687, Ser876, Ala879, Leu880, Lys883,
Lys884, Glu887, Lys996
Fluconazole Val129, Cys133, Ala136, Asn179, Glu180, Gly181, Gly183, Asp184,
Lys185, Met188, Leu875, Asp882, Lys930, Phe934
Pentamidine Glu239, Leu240, Ala242, Tyr243, Ala244, Gly247, Ala248, Glu251,
Arg785, Thr811, Ala815, Asn816, Ala819, Gln820
Miltefosine Asp173, Ser176, Lys177, Glu180, Lys185, Leu875, Ala879, Leu880, Lys883
Cladosporin Gln434, Leu437,Leu439, Val468, Ser470, Glu472, Val474,Asn899,
Arg901, Thr902, Ser905
Jaspamide Leu254, Ala255, Ala256, Ile257,Arg258, Thr259,Phe800, Asn805, Thr806,
Thr807, Gly808, Leu810, Glu1115, Ile1117
Nifurtimox Ala288, Asn292, Gln769, Gly770, Phe773, Gly774, Glu778, Ala819,
Gln820, Lys822, Gly823, Ser827, Phe990, Pro992
Praziquantel Leu254, Ala255, Ala256, Ile257,Arg258, Thr259, Phe800, Asn805, Thr806,
Thr807, Leu810, Ser1113
Dapsone Val474, Leu475, Phe476, Ala477, Gly521, Glu522, Lys523, Lys891,
Thr894, Glu895, Glu898, Asn899, His1003, Arg1006, Ile1007, Lys1010
Benznidazole Asp685, Val688, Pro689, Trp799, Asp802, Lys804, Asn805, Arg813,
His1003, Arg1006, Ile1007, Lys1010
Tipifarnib Ala244, Gly247, Ala248, Val249, Glu251, Glu252, Asp1120, Gly1166,
Asp1167, Lys1168
Flubendazole Phe159, Asp160, His162, Asp163, Val164, Ser470, Glu472, Val474, Ile897,
Gly898, Asn899, Phe900, Arg901, Thr902
Terbinafine Phe159, Val164, Gln434, Gln437, Leu439, Val468, Ser470, Glu472,
Val474, Ile897, Glu898, Asn899, Phe900, Arg901, Thr902, Ser905
Sodium
stibogluconate
Ser470, Glu472, Pro473, Val474, Leu475, Ala477, Glu522, Lys532, Glu895,
Glu898, Asn899, Arg901, Thr902
Paromomycin Val164, Glu472, Pro473, Val474, Glu522, Glu898, Asn899
Table 13.
Interacting residues between the P-glycoprotein of Leishmania major and the chosen drugs.
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Receptor Drug Interacting residues
4F4C Mebendazole Glu267, Thr268, Tyr271, Ala272, Gly275, Lys276, Lys315, Arg830,
Ala860, Thr861, Pro864, Arg867
Albendazole Glu36, Gly37, Asp38, Ile40, Glu267, Thr268, Tyr271, Val305, Ala308,
Lys309, Glu823, Thr826, Arg827, Arg830, Ala860, Thr861, Pro864,
Arg867
Suramin Lys720, Leu723, Ser724, Lys727, Lys923, Val925, Lys936
Diethylcarbamazine Arg918, Arg919, Phe920, Gly922, Lys923, Asn924, Gln979
Ivermectin Arg172, Thr197, Phe200, Asp201, Glu204, Lys720, Lys923, Asn924,
Val925, Ala928, Phe931, Ala932, Gly935, Lys936, Ile939
Praziquantel Leu11, Glu165, Lys207, Asp212, Arg918, Phe920, Lys923, Asn924,
Ser927, Phe931, Ala972, Glu975, Gln979
Moxidectin Leu11, Arg12, Asp15, Lys26, Lys30, Glu33, Pro374, Gln913, Tyr914,
Arg916, Gly917, Gly1032, Phe1033, Thr1035, Ser1036, Pro1039
Niclosamide Asn4, Gly5, Ser6, Leu7, Ile48, Thr49, Val56, Lys59, Gly380, Thr381,
Gln383, Gly384
Flubendazole Glu36, Gly37, Ser42, Thr268, Tyr271, Ala272, Gly275, Arg830,
Ala860, Thr861, Pro864, Asn865, Arg867, Lys1043
Thiabendazole Phe504, Asn505, Cys506, Asp933, Lys936, Ile937, Glu940, Phe957,
Asn960, Lys964
Metrifonate Gln840, His841, Gly843, Phe844, Ser847, Gln849, Asn850, Lys1057,
Ile1058, Lys1060
Emodepside Arg172, Thr197, Phe200, Asp201, Glu204, Asp550, Val925, Ser929,
Phe931, Ala932, Gly935, Lys936, Ile939
Table 14.
Interacting residues between the P-glycoprotein of Onchocerca volvulus and the chosen drugs.
Receptor Drug Interacting residues
4F4C Nifurtimox Asn733, Asn734, Gln849, Asn850, Arg1056, Lys1057, Ile1058
Benznidazole Asn4, Gly5, Ser6, Leu7, Thr49, Glu55, Val56, Arg205,Thr381,Gly384,
Ala385
Cladosporin Tyr35, Glu36, Ile40, Glu267, Thr268, Tyr271, Ala272, Gly275, Lys315,
Arg830, Ala860, Thr861, Arg867
Tipifarnib Gly373, Asp38, Ile40, Asp41, Ser42, Asn43, Glu267, Thr268, Tyr271,
Ala272, Gly275, Arg830, Ser856, Thr857, Ala860, Thr861, Arg867
Jaspamide Gln913, Tyr914, Arg916, Gly917, Arg918, Arg919, Lys923, Gly1032,
Ph1033, Thr1035, Ser1036, Phe1038, pro1039
Fexinidazole Gly37, Asp38, Ile40, Asp41, Ser42, Asn43, Thr268, Tyr271, Ala272, Gly275,
Arg830, Ser856, Ala860, Thr861, Pro864, Arg867
Suramin ,Lys727, Lys923, Val925
Ravuconazole Ala910, Gln913, Tyr914, Gly917, Arg919, Gly1032, Phe1033, Thr1035,
Ser1036, Pro1039
Posaconazole Glu33, Leu161, Gly917, Arg918, Arg919, Phe920, Gly922, Lys923, Asn924,
Glu975, Ala976, Gln979, Phe1033, Thr1035, Ser1036, Pro1039
Table 15.
Interacting residues between the P-glycoprotein of Schistosoma mansoni and the chosen drugs.
23
Computational Studies of Drug Repurposing Targeting P-Glycoprotein-Mediated…
DOI: http://dx.doi.org/10.5772/intechopen.93175
Please use Adobe Acrobat Reade  to read this book chapter for free.
Just open this sam  document with Adobe Reader.
If you do not have it, you can download it here.
You can freely access he chapter at the Web Viewer here.
Secur g Con ection...Acrobat is locking documen l ading.com
r
File cannot be found.
3.Schistosomiasis: Cladosporin (2.24 kcal/mol) and Jaspamide (2.23 kcal/
mol)
4.Onchocerciasis: Praziquantel (4.81 kcal/mol) and Moxidectin (4.18 kcal/
mol)
3.8 Analysis of interacting residues in each docked complex
The best pose of each docked complex was viewed using RasMol 2.1, and all
interacting residues within a radius of 4.5 Å of the ligand were restricted and
analyzed. The results are summarized in Tables 13–16.
The interacting residues are shown and the binding pockets found in each
protein sequence with respect to different drugs are highlighted. Analysis of the
interacting residues showed certain binding pockets in each efflux pump protein
studied. Certain residues were found to be preferred over others, for drug binding.
These preferred binding pockets are:
Receptor Drug Interacting residues
4F4C Praziquantel Asn505, Arg551, Asp933, Lys936, Ile937, Ile939, Glu940, Glu943, Asn944,
Lys964
Mebendazole Arg172, Thr197, Phe200, Asp201, Glu204, Lys207, Asn924, Ala928, Phe931,
Ala932, Gly935, Ile939
Oxamniquine Ile40, Asp41, Ser42, Thr268, Tyr271, Ala272,Gly275, Arg830, Ser856,
Ala860, Pro864, Arg867
Albendazole Ser42, Glu267, Thr268, Tyr271, Ala272, Gly275, Lys276, Lys315, Arg830,
Ala860, Arg867
Cladosporin Tyr35, Glu36, Gly37, Ile40, Phe263, Ala264, Ile265, Glu267, Thr268, Tyr271,
Lys315, Arg830, Thr861, Asn865, Arg867, Thr868, Glu1040, Lys1043
Jaspamide Leu161, Lys207, Glu208, Gly211, Asp212, Lys213, Gly917, Arg918, Arg919,
Phe920, Gly922, Lys923, Asn924, Gln979
Niclosamide Lys26 Lys30, Ala910, Gln913, Tyr914, Arg916, Gly917, Leu1031, Gly1032,
Phe1033,Thr1035
Nifurtimox Tyr35, Glu36, Gly37, Ile40, Phe263, Ala264, Glu267, Thr268, Lys315,
Pro864,Asn865, Arg867, Thr868, Glu1040, Lys1043
Artesunate Arg8, Leu11, Arg12,Asp15, Lys26, Lys30, Leu371, Pro374, Arg916, Phe1033,
Thr1035
Benznidazole Asn505, Arg551, Asp933, Lys936, Ile937, Glu940, Lys964
Tipifarnib Leu161, Glu204, Lys207, Glu208, Gly211, Asp212, Lys213, Val378, Asn924
Imatinib Ser42, Asn43, Glu267, Tr268, Tyr271, Ala272, Gly275, Lys276, Arg830,
Ala860, Thr861, Arg867,
Furozan Ala910, Gln913, Tyr914, Arg916, Gly917, Arg919, Lys923, Gly1032,
Thr1035, Ser1036, Phe1038, Pro1039
Suramin Asn4, Arg8, Asp51, Glu55, Thr194, Asp201, Asn202, Arg205, Glu716,
Gly719, Lys720, Asp721
Metrifonate Ile40, Phe263, Ala264, Glu267, Thr268, Tyr271, Ala308, Lys315, Arg830,
Ala860, Pro864, Arg867
Table 16.
Interacting residues between the P-glycoprotein of Trypanosoma cruzi and the chosen drugs.
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1.P-glycoprotein (Leishmania major): (Ser470, Glu472, Val474, Ile897,
Glu898, Asn899, Phe900, Arg901, Thr902, Ser905)
2.P-glycoprotein (Onchocerca volvulus): (Arg830, Ala860, Thr861, Pro864,
Arg867)
3.P-glycoprotein (Schistosoma mansoni): (Glu267, Thr268, Tyr271, Ala272,
Gly275, Lys276)
4.P-glycoprotein (Trypanosoma cruzi): (Arg830, Ala860, Thr861, Arg867);
(Gly917, Arg918, Arg919, Phe920, Gly922, Lys923); (Phe1033, Thr1035,
Ser1036, Pro1039)
3.9 P-glycoprotein in E. coli
A PSI-BLAST was performed to search for P-glycoprotein homologs in E. coli
using hPGP as the query. The top BLAST hits showed low percentage identity (<
30%) and low score and were not annotated as bacterial P-glycoprotein. Though we
could not reliably ascertain P-glycoprotein homologs in E. coli, there exist other
mechanisms that could potentially lead to multidrug resistance phenotypes in E.
coli. Multidrug efflux systems are of five types, namely the super-families ATP
Binding Cassete (ABC) and Major Facilitador Super-family (MFS), Small Multidrug
Resistance (SMR), Resistance, Nodulation, Division (RND) and Multidrug and
Toxic Compound Extrusion (MATE). In E.coli, the examples for various systems
include: MFS system Bcr, EmrB and EmrD; SMR family EmrE; RND family AcrB;
and Mate family YdhE9 [39]. E. coli contains five putative ABC-type MDR-like
transporters. These systems were all cloned and expressed in a drug-sensitive E. coli
strain, and the drug resistance phenotypes were investigated. None of these systems
provided an appreciable drug resistance to E. coli, except for YbjYZ, which con-
ferred resistance to erythromycin [40]. The AcrAB-TolC system of E. coli is one of
the best-characterized MDR transporters that is responsible for the acquisition of
multiple antimicrobial resistance of the mar mutants, including resistance to tetra-
cycline, chloramphenicol, ampicillin, nalidixic, and rifampicin [41, 42]. E. coli
infections could modulate the pharmacokinetics of the drug enrofloxacin by alter-
ing the expression of intestinal P-glycoprotein in broilers [43].
4. Conclusions
The study of the human P-glycoprotein homologs, namely the P-glycoproteins
of Leishmania major, Onchocerca volvulus, Schistosoma mansoni, and Trypanosoma
cruzi has provided an insight into their drug resistance mechanisms. The investiga-
tional drugs such as cladosporin, jaspamide, nifurtimox, and tipifarnib are strong
contenders for novel antihelminthic treatment. Known drugs such as praziquantel
and moxidectin have shown great promise for use as treatment against other
helminthic diseases.
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